ENVISIONING SUSTAINABILITY IN PERSONALISED MEDICINE: FONDO AIFA 5% AND THE ITALIAN EXAMPLE

F. Bocchio 1, M. Tizzoni 1, M. Calvi 1, A. Di Benedetto 2.
1 UOC Farmacia, Fondazione IRCCS Policlinico San Matteo Pavia. 2 Scuola di Specializzazione in Farmacia Ospedaliera, Università degli Studi di Milano.

**Background and Importance.** Sustainability in the era of personalized medicine represents one of the major problems due to a possible limited access to innovative therapies. Since 2003 the Agenzia Italiana del Farmaco (AIFA), along with the contribution of pharma industries, has established an innovative and unique program, namely “Fondo 5%” (1). The aim of this project is to allow innovative and highly expensive treatments to rare-disease patients. All these therapies have been approved by the European medicine agency (EMA) but before the AIFA authorization and reimbursement for the specific indication. A joined evaluation by physicians and clinical pharmacists, based on scientific literature, clinical reports, treatment plan and cost-estimate analysis, generates a patient-specific request for a peculiar drug not otherwise available through the conventional ways. AIFA is responsible for the scientific evaluation, the final authorization or rejection. Once the treatment plan has been approved by AIFA, the clinician is authorized to administer the therapy whose cost will be subsequently refunded by AIFA (2).

**Aim and Objectives.** To describe the Italian experience in order to improve the availability of the best, innovative therapies considering sustainability of the NHS.

**Materials and Methods.** Collecting and process of drug request for Fondo 5% and analysis of the clinical and economic impact.

**Results.** Period: Aug 2018-Sept 2019. 24 treatments authorized by AIFA. 70% oncologic patients with a disease response; moreover, 44% of AML have been undergone to bone marrow transplant. Total amount of authorized treatments: € 700.000, of which € 142.000 already credited back to the hospital.

<table>
<thead>
<tr>
<th>PATIENT</th>
<th>CLINICAL AREA</th>
<th>DRUGS</th>
<th>DIAGNOSIS</th>
<th>STATE OF TREATMENT</th>
<th>OUTCOME</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>GYNECOLOGICAL</td>
<td>Trabectedine</td>
<td>Ovaric carcinoma</td>
<td>ON GOING</td>
<td>EARLY RESPONSE</td>
</tr>
<tr>
<td>2</td>
<td>HEMATOLOGICAL</td>
<td>Venetoclax</td>
<td>AML</td>
<td>ON GOING</td>
<td>EARLY RESPONSE</td>
</tr>
<tr>
<td>3</td>
<td>HEMATOLOGICAL</td>
<td>Eltrombopag</td>
<td>Pure Aplasia</td>
<td>ON GOING</td>
<td>EARLY RESPONSE</td>
</tr>
<tr>
<td>4</td>
<td>HEMATOLOGICAL</td>
<td>Ruxolitinib</td>
<td>GVHD</td>
<td>ON GOING</td>
<td>EARLY RESPONSE</td>
</tr>
<tr>
<td>5</td>
<td>HEMATOLOGICAL</td>
<td>Ruxolitinib</td>
<td>Myeloproliferative neoplasm BCR-JAK2</td>
<td>ON GOING</td>
<td>EARLY RESPONSE</td>
</tr>
<tr>
<td>6</td>
<td>HEMATOLOGICAL</td>
<td>Ruxolitinib</td>
<td>GVHD</td>
<td>ON GOING</td>
<td>EARLY RESPONSE</td>
</tr>
<tr>
<td>7</td>
<td>HEMATOLOGICAL</td>
<td>Pembrolizumab</td>
<td>Hodgkin Lymphoma</td>
<td>ON GOING</td>
<td>EARLY RESPONSE</td>
</tr>
<tr>
<td>8</td>
<td>HEMATOLOGICAL</td>
<td>Venetoclax</td>
<td>MCL</td>
<td>ON GOING</td>
<td>EARLY RESPONSE</td>
</tr>
<tr>
<td>9</td>
<td>HEMATOLOGICAL</td>
<td>Pembrolizumab</td>
<td>Hodgkin Lymphoma</td>
<td>EOT</td>
<td>COMPLETE RESPONSE</td>
</tr>
<tr>
<td>10</td>
<td>HEMATOLOGICAL</td>
<td>Blinatumumab</td>
<td>ALL</td>
<td>EOT</td>
<td>COMPLETE RESPONSE</td>
</tr>
<tr>
<td>11</td>
<td>HEMATOLOGICAL</td>
<td>Venetoclax</td>
<td>AML</td>
<td>EOT</td>
<td>PROGRESSION DISEASE</td>
</tr>
<tr>
<td>12</td>
<td>HEMATOLOGICAL</td>
<td>Venetoclax</td>
<td>AML</td>
<td>EOT</td>
<td>TOXICITY</td>
</tr>
<tr>
<td>13</td>
<td>HEMATOLOGICAL</td>
<td>Trabectedine</td>
<td>Ovaric carcinoma</td>
<td>EOT</td>
<td>COMPLETE RESPONSE</td>
</tr>
<tr>
<td>14</td>
<td>HEMATOLOGICAL</td>
<td>Venetoclax</td>
<td>AML</td>
<td>EOT</td>
<td>PROGRESSION DISEASE</td>
</tr>
<tr>
<td>15</td>
<td>HEMATOLOGICAL</td>
<td>Venetoclax</td>
<td>AML</td>
<td>EOT</td>
<td>COMPLETE RESPONSE</td>
</tr>
<tr>
<td>16</td>
<td>HEMATOLOGICAL</td>
<td>Venetoclax</td>
<td>AML</td>
<td>EOT</td>
<td>PROGRESSION DISEASE</td>
</tr>
<tr>
<td>17</td>
<td>HEMATOLOGICAL</td>
<td>Venetoclax</td>
<td>AML</td>
<td>EOT</td>
<td>COMPLETE RESPONSE</td>
</tr>
<tr>
<td>18</td>
<td>HEMATOLOGICAL</td>
<td>Blinatumumab</td>
<td>ALL</td>
<td>EOT</td>
<td>COMPLETE RESPONSE</td>
</tr>
<tr>
<td>19</td>
<td>HEMATOLOGICAL</td>
<td>Venetoclax</td>
<td>AML</td>
<td>EOT</td>
<td>COMPLETE RESPONSE</td>
</tr>
<tr>
<td>20</td>
<td>HEMATOLOGICAL</td>
<td>Pembrolizumab</td>
<td>PMBCL</td>
<td>EOT</td>
<td>PROGRESSION DISEASE</td>
</tr>
<tr>
<td>21</td>
<td>HEMATOLOGICAL</td>
<td>Trabectedine</td>
<td>Ovaric adenocarcinoma</td>
<td>EOT</td>
<td>PROGRESSION DISEASE</td>
</tr>
<tr>
<td>22</td>
<td>HEMATOLOGICAL</td>
<td>Blinatumumab</td>
<td>ALL</td>
<td>EOT</td>
<td>COMPLETE RESPONSE</td>
</tr>
<tr>
<td>23</td>
<td>HEMATOLOGICAL</td>
<td>Blinatumumab</td>
<td>ALL</td>
<td>EOT</td>
<td>COMPLETE RESPONSE</td>
</tr>
<tr>
<td>24</td>
<td>OPHTHALMOLOGY</td>
<td>Ceneremin</td>
<td>Neurotrophic keratitis</td>
<td>EOT</td>
<td>COMPLETE RESPONSE</td>
</tr>
</tbody>
</table>

**Conclusion and Relevance.** These results demonstrate that Fondo 5% represents a scientific-based method able to guarantee the access to highly expensive therapeutic programs, impacting patients survival (96%), without affecting the cost-effectiveness balance and the NHS sustainability.

**References and/or Acknowledgements**
(1) L.326/2003. (2) www.aifa.gov.it/fondo-nazionale-aifa

No conflict of interest. Contact: f.bocchio@smatteo.pv.it

Abs N.: 1ISG-016